您的位置: 首页 > 农业专利 > 详情页

COMBINATIONS WITH A FIXED DOSE OF ALISKIREN AND AMLODIPINE IN THE FORM OF TWO-LAYERED OR SINGLE-LAYERED TABLETS
专利权人:
НОВАРТИС АГ (CH)
发明人:
ВАЛАЗЗА Стивен (US),УОГНЕР Роберт Франк (US),ВИППАГУНТА Судха (US)
申请号:
RU2011115712/15
公开号:
RU2011115712A
申请日:
2009.09.22
申请国别(地区):
RU
年份:
2012
代理人:
摘要:
1. A fixed dose pharmaceutical oral combination, including! a) a therapeutically effective amount of aliskiren or a pharmaceutically acceptable salt thereof, preferably a half-fumarate of said compound! b) a therapeutically effective amount of amlodipine or a pharmaceutically acceptable salt thereof, preferably a besylate of said compound! moreover, aliskiren is present in the form of a granulate in a mixture with at least one pharmaceutically acceptable additive! amlodipine is present in granular form in admixture with at least one pharmaceutically acceptable additive! a fixed dose pharmaceutical oral combination is characterized by an in vitro dissolution profile of component a) 60% or less after 10 minutes and 98% or less after 20 minutes, and a component dissolution profile b) 50% or more after 20 minutes and 70% or more after 30 min at pH 2.! 2. A fixed dose pharmaceutical oral combination, including! a) a therapeutically effective amount of aliskiren or a pharmaceutically acceptable salt thereof, preferably a half-fumarate of said compound! b) a therapeutically effective amount of amlodipine or a pharmaceutically acceptable salt thereof, preferably a besylate of said compound, wherein! - (1) aliskiren is present in the form of a granulate in a mixture with at least one pharmaceutically acceptable additive, optionally in the presence of a granulation liquid,! - (2) amlodipine is present in the form of a granulate in a mixture with at least one pharmaceutically acceptable additive,! - (3) the resulting corresponding aliskiren granules and amlodipine granules optionally in1. Фармацевтическая пероральная комбинация с фиксированной дозой, включающая ! а) терапевтически эффективное количество алискирена или его фармацевтически приемлемой соли, предпочтительно полуфумарата указанного соединения, ! б) терапевтически эффективное количество амлодипина или его фармацевтически приемлемой соли, предпочтительно безилата указанного соединения, ! причем алискирен присутств
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充